Serum anti-60s ribosomal protein L29 antibody as a novel prognostic marker for unresectable pancreatic cancer

Shinichiro Muro, Yasuhiro Miyake, Hironari Katou, Koichiro Tsutsumi, Kazuhide Yamamoto

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background/Aims: Recently, we found the presence of anti-60S ribosomal protein L29 antibody (anti-RPL29) in human sera, inhibiting the proliferation of pancreatic cancer cells in vitro. We aimed to estimate the association of serum anti-RPL29 levels with clinical features in patients affected with unresectable pancreatic cancer. Methods: We retrospectively reviewed 105 patients with unresectable pancreatic cancer. Serum anti-RPL29 levels were measured by the indirect enzyme-linked immunosorbent assay. The cut-off was represented by the 95th percentile in 62 healthy volunteers. Results: Median survival time (MST) was 11.1 months in 49 patients showing serum anti-RPL29 level >cut-off and 7.4 months in 56 patients showing serum anti-RPL29 level ≤cut-off. In locally advanced disease, MST was 17.9 months in 22 patients showing serum anti-RPL29 level >cut-off and 10.0 months in 19 patients showing serum anti-RPL29 level ≤cut-off. In metastatic disease, MST was 8.7 months in 27 patients showing serum anti-RPL29 level >cut-off and 5.9 months in 37 patients showing serum anti-RPL29 level ≤cut-off. In the multivariate Cox proportional hazard model, serum anti-RPL29 level >cut-off, abdominal or back pain, performance status, and metastatic disease were identified as independent prognostic factors. Conclusion: Serum anti-RPL29 levels may be a novel candidate for a prognostic marker for unresectable pancreatic cancer.

Original languageEnglish
Pages (from-to)164-173
Number of pages10
JournalDigestion
Volume91
Issue number2
DOIs
Publication statusPublished - Apr 6 2015

Fingerprint

Pancreatic Neoplasms
Antibodies
Serum
Survival
ribosomal protein L29
Back Pain
Proportional Hazards Models
Abdominal Pain
Healthy Volunteers
Enzyme-Linked Immunosorbent Assay

Keywords

  • Anti-tumor immune response
  • Antibody
  • Biomarker
  • Pancreatic cancer
  • Ribosomal protein L29

ASJC Scopus subject areas

  • Gastroenterology
  • Medicine(all)

Cite this

Serum anti-60s ribosomal protein L29 antibody as a novel prognostic marker for unresectable pancreatic cancer. / Muro, Shinichiro; Miyake, Yasuhiro; Katou, Hironari; Tsutsumi, Koichiro; Yamamoto, Kazuhide.

In: Digestion, Vol. 91, No. 2, 06.04.2015, p. 164-173.

Research output: Contribution to journalArticle

@article{950d4f98fb8040c5a1d02fd15e7e8e4d,
title = "Serum anti-60s ribosomal protein L29 antibody as a novel prognostic marker for unresectable pancreatic cancer",
abstract = "Background/Aims: Recently, we found the presence of anti-60S ribosomal protein L29 antibody (anti-RPL29) in human sera, inhibiting the proliferation of pancreatic cancer cells in vitro. We aimed to estimate the association of serum anti-RPL29 levels with clinical features in patients affected with unresectable pancreatic cancer. Methods: We retrospectively reviewed 105 patients with unresectable pancreatic cancer. Serum anti-RPL29 levels were measured by the indirect enzyme-linked immunosorbent assay. The cut-off was represented by the 95th percentile in 62 healthy volunteers. Results: Median survival time (MST) was 11.1 months in 49 patients showing serum anti-RPL29 level >cut-off and 7.4 months in 56 patients showing serum anti-RPL29 level ≤cut-off. In locally advanced disease, MST was 17.9 months in 22 patients showing serum anti-RPL29 level >cut-off and 10.0 months in 19 patients showing serum anti-RPL29 level ≤cut-off. In metastatic disease, MST was 8.7 months in 27 patients showing serum anti-RPL29 level >cut-off and 5.9 months in 37 patients showing serum anti-RPL29 level ≤cut-off. In the multivariate Cox proportional hazard model, serum anti-RPL29 level >cut-off, abdominal or back pain, performance status, and metastatic disease were identified as independent prognostic factors. Conclusion: Serum anti-RPL29 levels may be a novel candidate for a prognostic marker for unresectable pancreatic cancer.",
keywords = "Anti-tumor immune response, Antibody, Biomarker, Pancreatic cancer, Ribosomal protein L29",
author = "Shinichiro Muro and Yasuhiro Miyake and Hironari Katou and Koichiro Tsutsumi and Kazuhide Yamamoto",
year = "2015",
month = "4",
day = "6",
doi = "10.1159/000371545",
language = "English",
volume = "91",
pages = "164--173",
journal = "Digestion",
issn = "0012-2823",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Serum anti-60s ribosomal protein L29 antibody as a novel prognostic marker for unresectable pancreatic cancer

AU - Muro, Shinichiro

AU - Miyake, Yasuhiro

AU - Katou, Hironari

AU - Tsutsumi, Koichiro

AU - Yamamoto, Kazuhide

PY - 2015/4/6

Y1 - 2015/4/6

N2 - Background/Aims: Recently, we found the presence of anti-60S ribosomal protein L29 antibody (anti-RPL29) in human sera, inhibiting the proliferation of pancreatic cancer cells in vitro. We aimed to estimate the association of serum anti-RPL29 levels with clinical features in patients affected with unresectable pancreatic cancer. Methods: We retrospectively reviewed 105 patients with unresectable pancreatic cancer. Serum anti-RPL29 levels were measured by the indirect enzyme-linked immunosorbent assay. The cut-off was represented by the 95th percentile in 62 healthy volunteers. Results: Median survival time (MST) was 11.1 months in 49 patients showing serum anti-RPL29 level >cut-off and 7.4 months in 56 patients showing serum anti-RPL29 level ≤cut-off. In locally advanced disease, MST was 17.9 months in 22 patients showing serum anti-RPL29 level >cut-off and 10.0 months in 19 patients showing serum anti-RPL29 level ≤cut-off. In metastatic disease, MST was 8.7 months in 27 patients showing serum anti-RPL29 level >cut-off and 5.9 months in 37 patients showing serum anti-RPL29 level ≤cut-off. In the multivariate Cox proportional hazard model, serum anti-RPL29 level >cut-off, abdominal or back pain, performance status, and metastatic disease were identified as independent prognostic factors. Conclusion: Serum anti-RPL29 levels may be a novel candidate for a prognostic marker for unresectable pancreatic cancer.

AB - Background/Aims: Recently, we found the presence of anti-60S ribosomal protein L29 antibody (anti-RPL29) in human sera, inhibiting the proliferation of pancreatic cancer cells in vitro. We aimed to estimate the association of serum anti-RPL29 levels with clinical features in patients affected with unresectable pancreatic cancer. Methods: We retrospectively reviewed 105 patients with unresectable pancreatic cancer. Serum anti-RPL29 levels were measured by the indirect enzyme-linked immunosorbent assay. The cut-off was represented by the 95th percentile in 62 healthy volunteers. Results: Median survival time (MST) was 11.1 months in 49 patients showing serum anti-RPL29 level >cut-off and 7.4 months in 56 patients showing serum anti-RPL29 level ≤cut-off. In locally advanced disease, MST was 17.9 months in 22 patients showing serum anti-RPL29 level >cut-off and 10.0 months in 19 patients showing serum anti-RPL29 level ≤cut-off. In metastatic disease, MST was 8.7 months in 27 patients showing serum anti-RPL29 level >cut-off and 5.9 months in 37 patients showing serum anti-RPL29 level ≤cut-off. In the multivariate Cox proportional hazard model, serum anti-RPL29 level >cut-off, abdominal or back pain, performance status, and metastatic disease were identified as independent prognostic factors. Conclusion: Serum anti-RPL29 levels may be a novel candidate for a prognostic marker for unresectable pancreatic cancer.

KW - Anti-tumor immune response

KW - Antibody

KW - Biomarker

KW - Pancreatic cancer

KW - Ribosomal protein L29

UR - http://www.scopus.com/inward/record.url?scp=84924709163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924709163&partnerID=8YFLogxK

U2 - 10.1159/000371545

DO - 10.1159/000371545

M3 - Article

C2 - 25765324

AN - SCOPUS:84924709163

VL - 91

SP - 164

EP - 173

JO - Digestion

JF - Digestion

SN - 0012-2823

IS - 2

ER -